

CARRIER IN CARRIER: DNA-DOXORUBICIN COMPLEX SELF-ASSEMBLED WITH AMPHIPHILIC CYCLODEXTRINS AS NANOSYSTEMS FOR CANCER THERAPY †

Liliana P. Alarcón ¹, Heber Andrada ², Darío R. Falcone ², Fernando Silva ^{3*}, María E. Olivera ^{1*}

¹ Unit for Research and Development in Pharmaceutical Technology, CONICET and Department of Pharmaceutical Sciences, Faculty of Chemical Sciences, UNC, Córdoba, Argentina; liliana.alarcon@unc.edu.ar; lilipaola@gmail.com

² Institute for Agroindustrial Development and Health (IDAS). Chemistry Department. National University of Río Cuarto. Río Cuarto, Argentina.

³ Institute of Research in Physics-Chemistry of Córdoba, INFIQC-CONICET, FCQ, Department of Organic Chemistry, UNC, Córdoba, Argentina.

* Correspondence: M. E. O. eugenia.olivera@unc.edu.ar; F. S. fernando.silva@unc.edu.ar.

† Presented at 6th International Meeting of Pharmaceutical Sciences (RICiFa 2021), Córdoba, Argentina; November 10,11,12.

Received: ...; Revised: ...; Accepted: ...; Published: ...

Abstract:

The goal of the present work was to characterize the interaction between DNA–Doxorubicin (DNA–Dox) complex and cationic vesicles based on amphiphilic cyclodextrins (ModCBHD) for their application as drug delivery systems. The systems were characterized by dynamic light scattering (DLS), Zeta potential (ζ), circular dichroism (CD), Emission spectroscopy, atomic force microscope (AFM), transmission electron microscopy (TEM) and drug release in two-compartment Franz cells. Fluorescence spectra, CD profile and ζ showed multifaceted interaction pathways between DNA and Dox, with ionic and intercalation interactions, through the amino sugar residue and the tetracycline ring system of the drug, to form DNA-Dox complexes with a negative surface charge. DNA behaves as a reservoir of Dox, that is slowly released from the complex triggered by the presence of ions in the medium. ModCBHD-DNA-Dox complexes were formed by self-assembling in aqueous solution without introducing any subsequent steps, and exhibited around 160 nm particle size, monodisperse size distribution (PDI 0.250) and spherical shape, which could be an advantage for the enhanced permeability and retention (EPR) effect in cancer therapy. All these results demonstrated that ModCBHD can load the DNA-Dox complex and indicated the potential of the ModCBHD-DNA-Dox systems as nanocarriers to be evaluated in both in vitro cancer cell lines and in vivo tumor models.

Keywords: DNA-Doxorubicin complex; Amphiphilic Cyclodextrins; Cancer therapy; Drug delivery; vesicles.

© 2021 by the authors. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Funding

This research was funded by Secyt UNC Res 411/18, PIP CONICET 112-2015-0100283 and Foncyt (PICT -2015-3331; PICT 2018-0508).

Acknowledgments

L. P. A and H. A. thank for the CONICET fellowship. The authors thank to Filaxis S.A for Doxorubicin donation.

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.